跳至主要内容
临床试验/NCT01062659
NCT01062659撤回不适用

Characterization of Cellular Immune Responses in the Liver in Patients With Chronic Hepatitis C Virus Infection

University of Ulm1 个研究点 分布在 1 个国家开始时间: 2010年2月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1

研究概览

简要总结

In order to persist in the liver, HCV has numerous nonspecific and specific strategies to overcome the immunity of the host. The crucial step in the establishment of viral persistence and chronic hepatitis is the avoidance of specific antiviral cellular immune response in the liver. Treatment with pegylated interferon alpha (IFNα) in combination with ribavirin (RBV) is the standard therapy for chronic hepatitis C is. The response to IFNα / RBV therapy depends on the effective cellular antiviral immune response in the liver. The understanding of the interaction between HCV and cellular immune response is important for the effective use of existing diagnostic techniques, the Individual control and adjustment of the current therapeutic approaches and the development of future therapeutic and immunization strategies. In this study, the investigators want to investigate cellular Immune responses in the liver of HCV infected patients and characterize the influence of these immune responses to the response to IFNα / RBV therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • proven chronic hepatitis C
  • aged between 18 and 65
  • willingness to give written informed consent to the study protocol

排除标准

  • history of having received any IFN, PEG-IFN or RBV
  • not eligible for antiviral treatment with peginterferon and ribavirin by standard of care

研究者

发起方
University of Ulm
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dietmar M. Klass

Dr. med.

University of Ulm

研究点 (1)

Loading locations...

相似试验